In the third quarter of 2025, Meridian Growth Fund’s investor letter highlighted record high equities fueled by tech gains, tariff easing, and AI investments. The fund saw a -1.78% return compared to the Russell 2500 Growth Index’s 10.73% return. Check the top five holdings for the fund’s best picks this year.

Madrigal Pharmaceuticals, Inc. (MDGL) saw a one-month return of 44.78% and a 52-week gain of 87.41%. The stock closed at $596.98 per share on November 28, 2025, with a market cap of $13.558 billion. The company focuses on delivering therapeutics for metabolic dysfunction-associated steatohepatitis.

Meridian Growth Fund praised Madrigal Pharmaceuticals, Inc. (MDGL) in its Q3 2025 letter for its strong commercial launch of Rezdiffra, a drug therapy with billion-dollar sales potential. The company also has promising therapies in its pipeline, leading to a positive market outlook and trimming of positions based on valuation.

48 hedge fund portfolios held Madrigal Pharmaceuticals, Inc. (MDGL) in Q3 2025, up from 47 in the previous quarter. The company reported net sales of $287 million, up 35% quarter-over-quarter. While acknowledging its potential, some believe certain AI stocks offer greater upside potential and less downside risk.

Read more at Yahoo Finance: Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug